Skip to main content

Advertisement

SpringerLink
Log in

Disparities in Hormone Receptor-Positive Breast Cancer

  • Review
  • Published:
Current Breast Cancer Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

While the incidence of hormone receptor-positive, HER2-negative (HR + HER2-) breast cancer is lower for Black women compared to White women, the mortality rate is higher. This review highlights available data in four areas of disparities in HR + HER2- breast cancer: risk factors, tumor biology, treatment, and social determinants of health.

Recent Findings

Racial disparities persist in a variety of breast cancer-related outcomes in women with HR + breast cancer, despite adjustment for confounders. This emphasizes the multifactorial etiology of disparities in breast cancer outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Breast cancer facts & figures 2022–2024. Atlanta, GA, USA American Cancer Society 2022.

  2. •• Jatoi I, Sung H, Jemal A. The emergence of the racial disparity U.S. in breast-cancer mortality. N Engl J Med. 2022;386(25):2349–52. https://doi.org/10.1056/NEJMp2200244. (Discusses key reasons for the emergence of racial disparities in breast cancer mortality in the USA).

  3. Martini R, Newman L, Davis M. Breast cancer disparities in outcomes; unmasking biological determinants associated with racial and genetic diversity. Clin Exp Metastasis. 2022;39(1):7–14. https://doi.org/10.1007/s10585-021-10087-x.

    Article  CAS  PubMed  Google Scholar 

  4. Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast cancer statistics, 2022. CA A Cancer J Clin. 2022;72(6):524–41. https://doi.org/10.3322/caac.21754.

    Article  Google Scholar 

  5. Lovejoy LA, Shriver CD, Haricharan S, Ellsworth RE. Survival disparities in US Black compared to White women with hormone receptor positive-HER2 negative breast cancer. Int J Environ Res Public Health. 2023;20(4). https://doi.org/10.3390/ijerph20042903.

  6. O’Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, et al. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res. 2010;16(24):6100–10. https://doi.org/10.1158/1078-0432.CCR-10-1533.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, Edge SB, et al. Racial and ethnic differences in breast cancer survival: mediating effect of tumor characteristics and sociodemographic and treatment factors. J Clin Oncol. 2015;33(20):2254–61. https://doi.org/10.1200/JCO.2014.57.1349.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Lorona NC, Malone KE, Li CI. Racial/ethnic disparities in risk of breast cancer mortality by molecular subtype and stage at diagnosis. Breast Cancer Res Treat. 2021;190(3):549–58. https://doi.org/10.1007/s10549-021-06311-7.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Jemal A, Robbins AS, Lin CC, Flanders WD, DeSantis CE, Ward EM, et al. Factors that contributed to Black-White disparities in survival among nonelderly women with breast cancer between 2004 and 2013. J Clin Oncol. 2018;36(1):14–24. https://doi.org/10.1200/JCO.2017.73.7932.

    Article  PubMed  Google Scholar 

  10. Gaudet MM, Gierach GL, Carter BD, Luo J, Milne RL, Weiderpass E, et al. Pooled analysis of nine cohorts reveals breast cancer risk factors by tumor molecular subtype. Cancer Res. 2018;78(20):6011–21. https://doi.org/10.1158/0008-5472.CAN-18-0502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. John EM, Phipps AI, Hines LM, Koo J, Ingles SA, Baumgartner KB, et al. Menstrual and reproductive characteristics and breast cancer risk by hormone receptor status and ethnicity: the Breast Cancer Etiology in Minorities Study. Int J Cancer. 2020;147(7):1808–22. https://doi.org/10.1002/ijc.32923.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Adams-Campbell LL, Makambi KH, Palmer JR, Rosenberg L. Diagnostic accuracy of the Gail model in the Black Women’s Health Study. Breast J. 2007;13(4):332–6. https://doi.org/10.1111/j.1524-4741.2007.00439.x.

    Article  PubMed  Google Scholar 

  13. Porterhouse MD, Paul S, Lieberenz JL, Stempel LR, Levy MA, Alvarado R. Black women are less likely to be classified as high-risk for breast cancer using the Tyrer-Cuzick 8 model. Ann Surg Oncol. 2022;29(10):6419–25. https://doi.org/10.1245/s10434-022-12140-9.

    Article  PubMed  Google Scholar 

  14. • Ballinger TJ, Jiang G, Shen F, Miller KD, Sledge GW Jr, Schneider BP. Impact of African ancestry on the relationship between body mass index and survival in an early-stage breast cancer trial (ECOG-ACRIN E5103). Cancer. 2022;128(11):2174–81. https://doi.org/10.1002/cncr.34173. (Examines the interplay of genetic ancestry and BMI in disparate breast cancer outcomes in a large clinical trial population of patients treated with chemotherapy).

    Article  PubMed  Google Scholar 

  15. Costantino NS, Freeman B, Shriver CD, Ellsworth RE. Outcome disparities in African American compared with European American women with ER+HER2- tumors treated within an equal-access health care system. Ethn Dis. 2016;26(3):407–16. https://doi.org/10.18865/ed.26.3.407.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Parada H Jr, Sun X, Fleming JM, Williams-DeVane CR, Kirk EL, Olsson LT, et al. Race-associated biological differences among luminal A and basal-like breast cancers in the Carolina Breast Cancer Study. Breast Cancer Res. 2017;19(1):131. https://doi.org/10.1186/s13058-017-0914-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Barrow MA, Martin ME, Coffey A, Andrews PL, Jones GS, Reaves DK, et al. A functional role for the cancer disparity-linked genes, CRYbetaB2 and CRYbetaB2P1, in the promotion of breast cancer. Breast Cancer Res. 2019;21(1):105. https://doi.org/10.1186/s13058-019-1191-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Ruiz-Narvaez EA, Sucheston-Campbell L, Bensen JT, Yao S, Haddad S, Haiman CA, et al. Admixture mapping of African-American women in the AMBER Consortium identifies new loci for breast cancer and estrogen-receptor subtypes. Front Genet. 2016;7:170. https://doi.org/10.3389/fgene.2016.00170.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Chen JW, Murugesan K, Newberg JY, Sokol ES, Savage HM, Stout TJ, et al. Comparison of PIK3CA mutation prevalence in breast cancer across predicted ancestry populations. JCO Precis Oncol. 2022;6:e2200341. https://doi.org/10.1200/PO.22.00341.

    Article  PubMed  PubMed Central  Google Scholar 

  20. •• Miyashita M, Bell JSK, Wenric S, Karaesmen E, Rhead B, Kase M, et al. Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations. Breast Cancer Res. 2023;25(1):58. https://doi.org/10.1186/s13058-023-01627-2. (Highlights different gene expression profiles of a HR+HER2- breast cancer by genetic ancestry).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313(2):165–73. https://doi.org/10.1001/jama.2014.17322.

    Article  CAS  PubMed  Google Scholar 

  22. DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–51. https://doi.org/10.3322/caac.21583.

    Article  PubMed  Google Scholar 

  23. •• Wilkerson AD, Obi M, Ortega C, Sebikali-Potts A, Wei W, Pederson HJ, et al. Young Black women may be more likely to have first mammogram cancers: a new perspective in breast cancer disparities. Ann Surg Oncol. 2023;30(5):2856–69. https://doi.org/10.1245/s10434-022-12995-y. (HighlightstheimportanceofearlyscreeninginBlackwomenduetotheyoungerincidenceofbreastcancerasapotentialmitigatorofdisparities).

    Article  PubMed  Google Scholar 

  24. Kantor O, Wang ML, Bertrand K, Pierce L, Freedman RA, Chavez-MacGregor M, et al. Racial and socioeconomic disparities in breast cancer outcomes within the AJCC pathologic prognostic staging system. Ann Surg Oncol. 2022;29(1):686–96. https://doi.org/10.1245/s10434-021-10527-8.

    Article  PubMed  Google Scholar 

  25. Troester MA, Sun X, Allott EH, Geradts J, Cohen SM, Tse CK, et al. Racial differences in PAM50 subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst. 2018;110(2):176–82. https://doi.org/10.1093/jnci/djx135.

    Article  CAS  PubMed  Google Scholar 

  26. Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38(12):1346–66. https://doi.org/10.1200/JCO.19.02309.

    Article  PubMed  Google Scholar 

  27. Deyarmin B, Kane JL, Valente AL, van Laar R, Gallagher C, Shriver CD, et al. Effect of ASCO/CAP guidelines for determining ER status on molecular subtype. Ann Surg Oncol. 2013;20(1):87–93. https://doi.org/10.1245/s10434-012-2588-8.

    Article  PubMed  Google Scholar 

  28. Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, et al. Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann Oncol. 2014;25(5):1004–11. https://doi.org/10.1093/annonc/mdu053.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Purrington KS, Gorski D, Simon MS, Hastert TA, Kim S, Rosati R, et al. Racial differences in estrogen receptor staining levels and implications for treatment and survival among estrogen receptor positive, HER2-negative invasive breast cancers. Breast Cancer Res Treat. 2020;181(1):145–54. https://doi.org/10.1007/s10549-020-05607-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Benefield HC, Allott EH, Reeder-Hayes KE, Perou CM, Carey LA, Geradts J, et al. Borderline estrogen receptor-positive breast cancers in Black and White women. J Natl Cancer Inst. 2020;112(7):728–36. https://doi.org/10.1093/jnci/djz206.

    Article  CAS  PubMed  Google Scholar 

  31. Hoskins KF, Danciu OC, Ko NY, Calip GS. Association of race/ethnicity and the 21-gene recurrence score with breast cancer-specific mortality among US women. JAMA Oncol. 2021;7(3):370–8. https://doi.org/10.1001/jamaoncol.2020.7320.

    Article  PubMed  Google Scholar 

  32. Moore J, Wang F, Pal T, Reid S, Cai H, Bailey CE, et al. Oncotype DX risk recurrence score and total mortality for early-stage breast cancer by race/ethnicity. Cancer Epidemiol Biomarkers Prev. 2022;31(4):821–30. https://doi.org/10.1158/1055-9965.EPI-21-0929.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Ibraheem A, Olopade OI, Huo D. Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base. Cancer. 2020;126(17):4013–22. https://doi.org/10.1002/cncr.32956.

    Article  CAS  PubMed  Google Scholar 

  34. •• Albain KS, Gray RJ, Makower DF, Faghih A, Hayes DF, Geyer CE, et al. Race, ethnicity, and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial. J Natl Cancer Inst. 2021;113(4):390–9. https://doi.org/10.1093/jnci/djaa148. (Explores racial disparites in the TAILORx clinical trial and shows that although there are disparate outcomes by race and ethnicity, chemotherapy receipt does not mitigate worse outcomes in patients with a RS < 26).

    Article  CAS  PubMed  Google Scholar 

  35. Benefield HC, Reeder-Hayes KE, Nichols HB, Calhoun BC, Love MI, Kirk EL, et al. Outcomes of hormone-receptor positive, HER2-negative breast cancers by race and tumor biological features. JNCI Cancer Spectr. 2021;5(1). https://doi.org/10.1093/jncics/pkaa072.

  36. Li JJ, Tsang JY, Tse GM. Tumor microenvironment in breast cancer-updates on therapeutic implications and pathologic assessment. Cancers (Basel). 2021;13(16). https://doi.org/10.3390/cancers13164233.

  37. O’Meara T, Safonov A, Casadevall D, Qing T, Silber A, Killelea B, et al. Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women. Breast Cancer Res Treat. 2019;175(1):247–59. https://doi.org/10.1007/s10549-019-05156-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Yao S, Cheng TD, Elkhanany A, Yan L, Omilian A, Abrams SI, et al. Breast tumor microenvironment in Black women: a distinct signature of CD8+ T-cell exhaustion. J Natl Cancer Inst. 2021;113(8):1036–43. https://doi.org/10.1093/jnci/djaa215.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Kim G, Karadal-Ferrena B, Qin J, Sharma VP, Oktay IS, Lin Y, et al. Racial disparity in tumor microenvironment and distant recurrence in residual breast cancer after neoadjuvant chemotherapy. NPJ Breast Cancer. 2023;9(1):52. https://doi.org/10.1038/s41523-023-00547-w.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Haggstrom DA, Quale C, Smith-Bindman R. Differences in the quality of breast cancer care among vulnerable populations. Cancer. 2005;104(11):2347–58. https://doi.org/10.1002/cncr.21443.

    Article  PubMed  Google Scholar 

  41. Lund MJ, Brawley OP, Ward KC, Young JL, Gabram SS, Eley JW. Parity and disparity in first course treatment of invasive breast cancer. Breast Cancer Res Treat. 2008;109(3):545–57. https://doi.org/10.1007/s10549-007-9675-8.

    Article  PubMed  Google Scholar 

  42. Chen L, Li CI. Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status. Cancer Epidemiol Biomarkers Prev. 2015;24(11):1666–72. https://doi.org/10.1158/1055-9965.EPI-15-0293.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Freedman RA, Virgo KS, He Y, Pavluck AL, Winer EP, Ward EM, et al. The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer. 2011;117(1):180–9. https://doi.org/10.1002/cncr.25542.

    Article  PubMed  Google Scholar 

  44. Bleicher RJ, Ruth K, Sigurdson ER, Beck JR, Ross E, Wong Y-N, et al. Time to surgery and breast cancer survival in the United States. JAMA Oncol. 2016;2(3):330–9. https://doi.org/10.1001/jamaoncol.2015.4508.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Lee KT, Jacobs L, Walsh EM, Stearns V, Segal JB. Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer. Breast Cancer Res Treat. 2020;184(3):965–75. https://doi.org/10.1007/s10549-020-05910-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Fasano GA, Bayard S, Gillot T, Hannibal Z, Pedreira M, Newman L. Disparities in time to treatment for breast cancer: existing knowledge and future directions in the COVID-19 Era. Curr Breast Cancer Rep. 2022;14(4):213–21. https://doi.org/10.1007/s12609-022-00469-9.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, Giordano SH. Delayed initiation of adjuvant chemotherapy among patients with breast cancer. JAMA Oncol. 2016;2(3):322–9. https://doi.org/10.1001/jamaoncol.2015.3856.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Fu F, Yu L, Zeng B, Chen M, Guo W, Chen L, et al. Association of adjuvant hormone therapy timing with overall survival among patients with hormone receptor-positive human epidermal growth factor receptor-2-negative early breast cancer without chemotherapy. JAMA Netw Open. 2022;5(2):e2145934. https://doi.org/10.1001/jamanetworkopen.2021.45934.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Hoppe EJ, Hussain LR, Grannan KJ, Dunki-Jacobs EM, Lee DY, Wexelman BA. Racial disparities in breast cancer persist despite early detection: analysis of treatment of stage 1 breast cancer and effect of insurance status on disparities. Breast Cancer Res Treat. 2019;173(3):597–602. https://doi.org/10.1007/s10549-018-5036-z.

    Article  PubMed  Google Scholar 

  50. Reeder-Hayes KE, Meyer AM, Dusetzina SB, Liu H, Wheeler SB. Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer. Breast Cancer Res Treat. 2014;145(3):743–51. https://doi.org/10.1007/s10549-014-2957-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Camacho FT, Tan X, Alcala HE, Shah S, Anderson RT, Balkrishnan R. Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors. Medicine (Baltimore). 2017;96(24):e7147. https://doi.org/10.1097/MD.0000000000007147.

    Article  PubMed  Google Scholar 

  52. Bowles EJA, Ramin C, Buist DSM, Feigelson HS, Weinmann S, Veiga LHS, et al. Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001–2016. Breast Cancer Res Treat. 2022;193(1):203–16. https://doi.org/10.1007/s10549-022-06561-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Sheppard VB, Oppong BA, Hampton R, Snead F, Horton S, Hirpa F, et al. Disparities in breast cancer surgery delay: the lingering effect of race. Ann Surg Oncol. 2015;22(9):2902–11. https://doi.org/10.1245/s10434-015-4397-3.

    Article  PubMed  Google Scholar 

  54. Spencer JC, Reeve BB, Troester MA, Wheeler SB. Factors associated with endocrine therapy non-adherence in breast cancer survivors. Psychooncology. 2020;29(4):647–54. https://doi.org/10.1002/pon.5289.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529–37. https://doi.org/10.1007/s10549-010-1132-4.

    Article  CAS  PubMed  Google Scholar 

  56. Biggers A, Shi Y, Charlson J, Smith EC, Smallwood AJ, Nattinger AB, et al. Medicare D subsidies and racial disparities in persistence and adherence with hormonal therapy. J Clin Oncol. 2016;34(36):4398–404. https://doi.org/10.1200/JCO.2016.67.3350.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Farias AJ, Du XL. Association between out-of-pocket costs, race/ethnicity, and adjuvant endocrine therapy adherence among medicare patients with breast cancer. J Clin Oncol. 2017;35(1):86–95. https://doi.org/10.1200/JCO.2016.68.2807.

    Article  PubMed  Google Scholar 

  58. Kantor O, Chang C, Yao K, Boughey J, Roland C, Francescatti AB, et al. Uptake of breast cancer clinical trials at minority serving cancer centers. Ann Surg Oncol. 2021;28(9):4995–5004. https://doi.org/10.1245/s10434-020-09533-z.

    Article  PubMed  Google Scholar 

  59. Albain KS, Unger JM, Crowley JJ, Coltman CA Jr, Hershman DL. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst. 2009;101(14):984–92. https://doi.org/10.1093/jnci/djp175.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Kantor O, King TA, Freedman RA, Mayer EL, Chavez-MacGregor M, Korde LA, et al. Racial and ethnic disparities in locoregional recurrence among patients with hormone receptor–positive, node-negative breast cancer: a post hoc analysis of the TAILORx randomized clinical trial. JAMA Surg. 2023. https://doi.org/10.1001/jamasurg.2023.0297.

    Article  PubMed  Google Scholar 

  61. • Kim G, Pastoriza JM, Qin J, Lin J, Karagiannis GS, Condeelis JS, et al. Racial disparity in distant recurrence-free survival in patients with localized breast cancer: a pooled analysis of National Surgical Adjuvant Breast and Bowel Project trials. Cancer. 2022;128(14):2728–35. https://doi.org/10.1002/cncr.34241. (PooledanalysesofNSABPtrialdatasuggestingoutcomesdisparitiesinHR+butnotHR-breastcancersinpatientstreatedontheseclinicaltrials).

    Article  CAS  PubMed  Google Scholar 

  62. Alsan M, Wanamaker M. Tuskegee and the health of Black men*. Q J Econ. 2017;133(1):407–55. https://doi.org/10.1093/qje/qjx029.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Bilani N, El Ladki S, Yaghi M, Main O, Jabbal IS, Elson L, et al. Factors associated with the decision to decline chemotherapy in patients with early-stage, ER+/HER2- breast cancer and high-risk scoring on genomic assays. Clin Breast Cancer. 2022;22(4):367–73. https://doi.org/10.1016/j.clbc.2022.01.007.

    Article  CAS  PubMed  Google Scholar 

  64. Moore AD, Hamilton JB, Pierre-Louis BJ, Jennings BM. Increasing access to care and reducing mistrust: important considerations when implementing the patient-centered medical home in army health clinics. Mil Med. 2013;178(3):291–8. https://doi.org/10.7205/milmed-d-12-00443.

    Article  PubMed  Google Scholar 

  65. U.S. Department of Health and Human Services. Healthy People 2030. https://health.gov/healthypeople/priority-areas/social-determinants-health. Accessed July 2023.

  66. Beyer KM, Zhou Y, Matthews K, Bemanian A, Laud PW, Nattinger AB. New spatially continuous indices of redlining and racial bias in mortgage lending: links to survival after breast cancer diagnosis and implications for health disparities research. Health Place. 2016;40:34–43. https://doi.org/10.1016/j.healthplace.2016.04.014.

    Article  PubMed  Google Scholar 

  67. Collin LJ, Gaglioti AH, Beyer KM, Zhou Y, Moore MA, Nash R, et al. Neighborhood-level redlining and lending bias are associated with breast cancer mortality in a large and diverse metropolitan area. Cancer Epidemiol Biomarkers Prev. 2021;30(1):53–60. https://doi.org/10.1158/1055-9965.EPI-20-1038.

    Article  CAS  PubMed  Google Scholar 

  68. Coughlin SS. Social determinants of breast cancer risk, stage, and survival. Breast Cancer Res Treat. 2019;177(3):537–48. https://doi.org/10.1007/s10549-019-05340-7.

    Article  PubMed  Google Scholar 

  69. Sadigh G, Gray RJ, Sparano JA, Yanez B, Garcia SF, Timsina LR, et al. Assessment of racial disparity in survival outcomes for early hormone receptor-positive breast cancer after adjusting for insurance status and neighborhood deprivation: a post hoc analysis of a randomized clinical trial. JAMA Oncol. 2022;8(4):579–86. https://doi.org/10.1001/jamaoncol.2021.7656.

    Article  PubMed  PubMed Central  Google Scholar 

  70. John EM, McGuire V, Kurian AW, Koo J, Shariff-Marco S, Gomez SL, et al. Racial/ethnic disparities in survival after breast cancer diagnosis by estrogen and progesterone receptor status: a pooled analysis. Cancer Epidemiol Biomarkers Prev. 2021;30(2):351–63. https://doi.org/10.1158/1055-9965.EPI-20-1291.

    Article  CAS  PubMed  Google Scholar 

  71. Parise CA, Caggiano V. The influence of socioeconomic status on racial/ethnic disparities among the ER/PR/HER2 breast cancer subtypes. J Cancer Epidemiol. 2015;2015:813456. https://doi.org/10.1155/2015/813456.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Kirby JB, Kaneda T. ‘Double jeopardy’ measure suggests Blacks and Hispanics face more severe disparities than previously indicated. Health Aff (Millwood). 2013;32(10):1766–72. https://doi.org/10.1377/hlthaff.2013.0434.

    Article  PubMed  Google Scholar 

  73. Mootz A, Arjmandi F, Dogan BE, Evans WP. Health care disparities in breast cancer: the economics of access to screening, diagnosis, and treatment. J Breast Imaging. 2020;2(6):524–9. https://doi.org/10.1093/jbi/wbaa093.

    Article  Google Scholar 

  74. Tsapatsaris A, Babagbemi K, Reichman MB. Barriers to breast cancer screening are worsened amidst COVID-19 pandemic: a review. Clin Imaging. 2022;82:224–7. https://doi.org/10.1016/j.clinimag.2021.11.025.

    Article  PubMed  Google Scholar 

  75. Ellis L, Canchola AJ, Spiegel D, Ladabaum U, Haile R, Gomez SL. Trends in cancer survival by health insurance status in California from 1997 to 2014. JAMA Oncol. 2018;4(3):317–23. https://doi.org/10.1001/jamaoncol.2017.3846.

    Article  PubMed  Google Scholar 

  76. Hoffman HJ, LaVerda NL, Levine PH, Young HA, Alexander LM, Patierno SR, et al. Having health insurance does not eliminate race/ethnicity-associated delays in breast cancer diagnosis in the District of Columbia. Cancer. 2011;117(16):3824–32. https://doi.org/10.1002/cncr.25970.

    Article  PubMed  Google Scholar 

  77. Ko NY, Hong S, Winn RA, Calip GS. Association of insurance status and racial disparities with the detection of early-stage breast cancer. JAMA Oncol. 2020;6(3):385–92. https://doi.org/10.1001/jamaoncol.2019.5672.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Freeman HP, Chu KC. Determinants of cancer disparities: barriers to cancer screening, diagnosis, and treatment. Surg Oncol Clin N Am. 2005;14(4):655–69. https://doi.org/10.1016/j.soc.2005.06.002. (v).

    Article  PubMed  Google Scholar 

  79. Hasnain-Wynia R, Baker DW, Nerenz D, Feinglass J, Beal AC, Landrum MB, et al. Disparities in health care are driven by where minority patients seek care: examination of the hospital quality alliance measures. Arch Intern Med. 2007;167(12):1233–9. https://doi.org/10.1001/archinte.167.12.1233.

    Article  PubMed  Google Scholar 

  80. Rauscher GH, Allgood KL, Whitman S, Conant E. Disparities in screening mammography services by race/ethnicity and health insurance. J Womens Health (Larchmt). 2012;21(2):154–60. https://doi.org/10.1089/jwh.2010.2415.

    Article  PubMed  Google Scholar 

  81. Kozick Z, Hashmi A, Dove J, Hunsinger M, Arora T, Wild J, et al. Disparities in compliance with the Oncotype DX breast cancer test in the United States: a National Cancer Data Base assessment. Am J Surg. 2018;215(4):686–92. https://doi.org/10.1016/j.amjsurg.2017.05.008.

    Article  PubMed  Google Scholar 

  82. Unger JM, Moseley AB, Cheung CK, Osarogiagbon RU, Symington B, Ramsey SD, et al. Persistent disparity: socioeconomic deprivation and cancer outcomes in patients treated in clinical trials. J Clin Oncol. 2021;39(12):1339–48. https://doi.org/10.1200/JCO.20.02602.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Joshi S, Garlapati C, Aneja R. Epigenetic determinants of racial disparity in breast cancer: looking beyond genetic alterations. Cancers (Basel). 2022;14(8). https://doi.org/10.3390/cancers14081903.

  84. Mehrotra J, Ganpat MM, Kanaan Y, Fackler MJ, McVeigh M, Lahti-Domenici J, et al. Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. Clin Cancer Res. 2004;10(6):2052–7. https://doi.org/10.1158/1078-0432.ccr-03-0514.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

EAM acknowledges support as the Rob and Karen Hale Distinguished Chair in Surgical Oncology. The authors thank Valerie Hope Goldstein for her editorial assistance with manuscript preparation and submission.

Author information

Author notes

  1. Elizabeth A. Mittendorf and Olga Kantor contributed equally to mentoring ERO in writing this manuscript.

Authors and Affiliations

  1. Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, 450 Brookline Ave, Yawkey Suite 1220, Boston, MA, 02215, USA

    Esther R. Ogayo, Elizabeth A. Mittendorf & Olga Kantor

  2. Breast Oncology Program, Dana Farber-Cancer Institute, Boston, MA, USA

    Esther R. Ogayo, Elizabeth A. Mittendorf & Olga Kantor

  3. Harvard Medical School, Boston, MA, USA

    Esther R. Ogayo, Elizabeth A. Mittendorf & Olga Kantor

Authors
  1. Esther R. Ogayo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elizabeth A. Mittendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Olga Kantor
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

ERO wrote the main manuscript text and prepared the table and figure. EAM and OK edited the manuscript. All authors reviewed and approved the final version of the manuscript.

Corresponding author

Correspondence to Olga Kantor.

Ethics declarations

Competing Interests

EAM reports compensated service on scientific advisory boards for Astra Zeneca, BioNTech and Merck; uncompensated service on steering committees for Bristol Myers Squibb and Roche/Genentech; and institutional research support from Roche/Genentech (via SU2C grant) and Gilead. EAM also reports research funding from Susan Komen for the Cure for which she serves as a Scientific Advisor, and uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. ERO and OK report no disclosures.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ogayo, E.R., Mittendorf, E.A. & Kantor, O. Disparities in Hormone Receptor-Positive Breast Cancer. Curr Breast Cancer Rep 16, 106–115 (2024). https://doi.org/10.1007/s12609-024-00529-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12609-024-00529-2

Keywords

Search

Navigation